Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Helps, Yet It Is Underused in Some with NLPHL

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 22; Bismarck, et al

Radiotherapy (RT) is linked with longer overall survival in patients with any stage of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL), according to a study involving nearly 2,000 individuals. Still, it is less likely to be used in those who are in an advanced-stage and have B-symptoms. Participants were a median 46 years of age and were diagnosed with NLPHL between 2004 and 2012. Investigators looked at overall survival and survival differences between treatment groups. Among the results:

  • Increasing age, black race, Medicare insurance, chemotherapy use, stage II-IV disease, and presence of B-symptoms predicted RT omission.
  • Overall, patients receiving RT survived ~50 months, vs ~42 months for those who didn’t receive such, even after multivariate analysis.
  • Patients with B symptoms who received RT survived an average of 49 months, vs ~43 months for those who didn’t receive such.

Citation:

Bismarck O, Boothe D, Frandsen J, Poppe M, Gaffney D. The role of radiation in all stages of nodular lymphocytic predominant Hodgkin lymphoma. [Published online ahead of print September 22, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.013.

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018